Name	Indications
Peginterferon alfa-2b (PEG-Intron)	Treatment of chronic hepatitis C in patients not previously treated with interferon alfa who have compensated liver disease and are at least 18 years of age
Alemtuzumab (Campath)	Treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and failed fludarabine therapy
Hepatitis A inactivated and hepatitis B (recombinant) vaccine (Twinrix)	Active immunization of persons 18 years or older against hepatitis A virus infection and all known subtypes of hepatitis B virus infection
Digoxin immune fab, ovine (DigiFab)	Treatment of patients with life-threatening or potentially life-threatening cardiac glycoside toxicity or overdose
Darbepoetin alfa (Aranesp)	Treatment of anemia associated with chronic renal failure, whether or not patient is on dialysis
UltraQual hepatitis C virus reverse transcriptase polymerase chain reaction (PCR) assay	A nucleic acid test used to detect HCV-RNA in pooled human source plasma
UltraQual human immunodeficiency virus type 1 reverse transcriptase PCR assay	A nucleic acid test used to detect HIV-1-RNA in pooled human source plasma
Hepatitis B immune globulin, human (Nabi-HB)	For postexposure prophylaxis of hepatitis infection
Anakinra (Kineret)	For reduction in signs and symptoms of moderately to severely active rheumatoid arthritis, in patients 18 years or older who have failed one or more disease modifying antirheumatic drugs
Drotrecogin alfa, activated (Xigris)	Reduction of mortality in adult patients with severe sepsis (sepsis associated with acute organ dysfunction) who have a high risk of death (e.g., as determined by APACHE II)
Acellular pertussis vaccine, concentrate	New formulation: preservative-free
Diphtheria and tetanus toxoids and acellular pertussis vaccine, adsorbed (Tripedia)	New formulation: preservative-free, single-dose vial (reduced thimerosal)
Basiliximab (Simulect)	Expanded indication: use in renal transplantation in combination with triple immunosuppressive therapy; use in pediatric renal transplantation; and use an intravenous bolus injection
Rituximab (Rituxan)	New dosing regimen: retreatment of patients with non-Hodgkin's lymphoma and administration of eight weekly doses; other changes to package insert: updated response data, data on treatment of bulky disease, warning about severe mucocutaneous reactions
Peginterferon alfa-2b (PEG-Intron)	Expanded indication: combination therapy with ribavirin, USP (Rebetol), for treatment of chronic hepatitis C
Alteplase (Cathflo Activase)	New indication and dosing strength: 2-mg vial strength for the restoration of function to central venous access devices (as assessed by the ability to withdraw blood)